Dr. Goy on CAR-Modified T Cells in Lymphoma
Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.
Andre Goy, MD, MS, the Chief of the Division of Lymphoma at the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted chimeric antigen receptor (CAR)-modified T cells as a treatment for patients with various types of lymphoma.
Several versions of CAR-modified T cells exist, each with different side effects and constructs. However, when the evidence on each is taken together, the proof of principle is quite amazing, Goy believes.
The treatments can be utilized in a variety of settings. In some cases, the T cells are modified in the relapsed setting, following an allogeneic transplant. Additionally, autologous T cells can be utilized in the case of aggressive lymphomas, where there is only a small chance for relapse. In some studies, these treatments were used as a consolidative therapy, post-transplant, Goy states.
Ultimately, this will be a very important tool in lymphoma, Goy believes. These engineered T cell therapies are the ideal vaccines, since they are a cell therapy that persists to fights against recurrence, Goy believes. In general, these agents work by depleting CD19-positive B cells, which make antibodies. As a result of this mechanism, most patients will require lifetime intravenous immunoglobulin.
As research moves forward, Goy hopes the technology will evolve to provide further control for the lifespan of the T cells. These treatments hold the potential to completely change the treatment landscape in lymphoma, Goy states.
<<<
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
